Some multinationals to stage uphill battle in maintaining initial insurance price

Despite their favorable ruling over the trial to confirm the scope of patent rights, some multinational drug manufacturers, such as Pfizer and Sanofi-Aventis, are unlikely to see their reduced insurance prices to the initial level, according to the Ministry of Health, Welfare and Family Affairs.

A ministry official said that the trial to confirm the scope of patent rights cannot prevent cutb...